Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation

INTRODUCTION: Omalizumab is a monoclonal anti-immunoglobulin E antibody developed for the treatment of severe allergic asthma. The number of exacerbations used as a parameter of omalizumab therapy efficacy may be insufficient in many cases due to a relatively short time to first evaluation (16 weeks...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Postepy Dermatol Alergol
Hoofdauteurs: Skiepko, Roman, Ziętkowski, Ziemowit, Łukaszyk, Mateusz, Budny, Wojciech, Skiepko, Urszula, Milewski, Robert, Bodzenta-Łukaszyk, Anna
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Termedia Publishing House 2014
Onderwerpen:
Original Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4221351/
https://ncbi.nlm.nih.gov/pubmed/25395927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/pdia.2014.40973
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items